Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1107 in Advanced Solid Tumors
NCT06171789Phase 2Terminated
- Sponsor
- Genmab
- Start
- Jan 2024
- Primary completion
- Aug 2025
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of pro1107 in ovarian cancer, endometrial cancer (EC), triple-negative breast cancer (TNBC) and 3 more, sponsored by Genmab. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events and Number of Participants With Dose Limiting Toxicities at 28 days. Started Jan 2024; status: terminated.
02
Drugs
pro1107
03
Conditions
ovarian cancerendometrial cancer (EC)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT06171789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06171789.